BP-C1 in Short-term Treatment of Metastatic Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

December 19, 2014

Primary Completion Date

March 4, 2016

Study Completion Date

March 4, 2016

Conditions
Metastatic Pancreatic CancerUnresectable Pancreatic Cancer
Interventions
DRUG

BP-C1

BP-C1, 0.05% solution for injections; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days

DRUG

BP-C2

BP-C2, 0.15% solution for oral use; 15 ml orally once daily for 32 consecutive days

Trial Locations (1)

Unknown

National Liver Institute, Menoufia University, Cairo

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Meddoc

OTHER

collaborator

Norwegian University of Life Sciences

OTHER

lead

Meabco A/S

INDUSTRY

NCT03627390 - BP-C1 in Short-term Treatment of Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter